Diligence memo · auto-generated · as of July 2, 2026
Crosslink Therapeutics Inc.
Crosslink Therapeutics Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Crosslink Therapeutics Inc. operates in Pharmaceuticals, based in BOSTON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Crosslink Therapeutics Inc. has raised $4.3M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.3M on 2025-04-17.
Most recent recorded round closed around 2025-04-17.
Valuation (modeled)modeled
Provath models Crosslink Therapeutics Inc. at approximately $15M (range $4.9M–$28M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.95× the median modeled value of Series A Pharmaceuticals companies in 2025–2027 (37 peers) — value vs value, same stage and era. Within the normal band (95% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 14 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 39% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 23% of those peers.
Closest niche peers: Incannex Healthcare Inc., Retension Pharmaceuticals, Inc., Eikonoklastes Therapeutics, Inc., Phoenicis Therapeutics, Inc., Pharmaceutical Resource Technology, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.